Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab. - sprookjes - yvandenbroek - TriplyDB

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.

http://www.wikidata.org/entity/Q34679166

about

Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks?Next-generation prognostic assessment for diffuse large B-cell lymphoma Treatment of diffuse large B cell lymphoma Beyond RCHOP: A Blueprint for Diffuse Large B Cell Lymphoma Research.Cell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.Diffuse large B-cell lymphoma: can genomics improve treatment options for a curable cancer?Immunohistochemical and molecular characteristics with prognostic significance in diffuse large B-cell lymphoma.Molecular Testing of Lymphoproliferative Disorders: Current Status and Perspectives.Diffuse large B cell lymphoma: using pathologic and molecular biomarkers to define subgroups for novel therapy.The significance of FOXP1 in diffuse large B-cell lymphoma.BCL2 antibodies targeted at different epitopes detect varying levels of protein expression and correlate with frequent gene amplification in diffuse large B-cell lymphoma Poor concordance among nine immunohistochemistry classifiers of cell-of-origin for diffuse large B-cell lymphoma: implications for therapeutic strategies Primary central nervous system diffuse large B-cell lymphoma in the immunocompetent: Immunophenotypic subtypes and Epstein-Barr virus association.Frequency and extent of CD30 expression in diffuse large B-cell lymphoma and its relation to clinical and biologic factors: a retrospective study of 167 cases.Clinicopathologic analysis of localized nasal/paranasal diffuse large B-cell lymphoma Evaluating cell-of-origin subtype methods for predicting diffuse large B-cell lymphoma survival: a meta-analysis of gene expression profiling and immunohistochemistry algorithms MYC protein expression in primary diffuse large B-cell lymphoma of the central nervous system Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era.Immunohistochemical algorithm alone is not enough for predicting the outcome of patients with diffuse large B-cell lymphoma treated with R-CHOP Immunostaining to identify molecular subtypes of diffuse large B-cell lymphoma in a population-based epidemiologic study in the pre-rituximab era.The histological classification of diffuse large B-cell lymphomas Subtype distribution of lymphomas in Southwest China: analysis of 6,382 cases using WHO classification in a single institution Diffuse large B-cell lymphoma classification system that associates normal B-cell subset phenotypes with prognosis Aggressive B-cell lymphomas: how many categories do we need?DUSP4 deficiency caused by promoter hypermethylation drives JNK signaling and tumor cell survival in diffuse large B cell lymphoma Intravascular large B-cell lymphoma: report of three cases and analysis of the mTOR pathway.Multiparameter analysis of homogeneously R-CHOP-treated diffuse large B cell lymphomas identifies CD5 and FOXP1 as relevant prognostic biomarkers: report of the prospective SAKK 38/07 study.Molecular classification, pathway addiction, and therapeutic targeting in diffuse large B cell lymphoma Epstein-Barr virus positive diffuse large B-cell lymphoma predict poor outcome, regardless of the age.Personalized therapy in endometrial cancer: challenges and opportunities.Genetic lesions in diffuse large B-cell lymphomas TBL1XR1/TP63: a novel recurrent gene fusion in B-cell non-Hodgkin lymphoma.Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL.A new biologic prognostic model based on immunohistochemistry predicts survival in patients with diffuse large B-cell lymphoma Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.The histological and biological spectrum of diffuse large B-cell lymphoma in the World Health Organization classification Lymphomagenic CARD11/BCL10/MALT1 signaling drives malignant B-cell proliferation via cooperative NF-κB and JNK activation Prognostic significance of Epstein-Barr virus DNA detection in pretreatment serum in diffuse large B-cell lymphoma.The distinct clinical features and prognosis of the CD10⁺MUM1⁺ and CD10⁻Bcl6⁻MUM1⁻ diffuse large B-cell lymphoma.

P2860

Q24597424-2EA9FB84-49C1-431D-9068-2D1482575AAB Q26796428-0179F8B8-3B60-4821-B073-B115EABB542E Q27006062-DDB0DDF4-ACB5-42E2-96AB-C50AE1AE6DA9 Q30275206-FB27B679-3A02-476F-8CFA-4010E198A4E0 Q33591789-AA862200-CEBD-4B78-8F26-4820A513F0CC Q33622342-1EF57A40-54CE-4780-9F7E-55712B928613 Q33700531-B3852AA0-EDA2-403A-B9FF-19C8A9C1740F Q33729711-FADE947A-61C1-4A80-9B43-EE5182A24BE7 Q33846801-31D79D37-48B9-4613-9197-026715E05B5B Q34047455-23B901BC-2AF2-42E3-A97A-79880C3C8066 Q34339662-F06668C0-EEDD-4818-9DE1-8CA3ABE748EB Q34390837-429358B4-0D9C-46A2-89E2-866FA702E928 Q34574781-045B3A91-C166-42B4-9B1D-AFEAD8112976 Q34595732-DA42BE89-3DDB-4A75-9B8B-83573843578A Q34612336-30DEB15A-5164-4796-8C49-88A062A7208F Q34617849-A273C25D-A138-4747-9B97-5E71C6D69E79 Q34640550-BA76AD9C-C396-4663-BA9F-3C6AFDBE75AF Q34882773-C8966943-BC1B-4264-A8C4-8433097732F2 Q35145270-3DDC9861-CE75-44F5-A928-9505342D5A19 Q35193836-BB6401B6-CA8E-4B91-8882-AE62F6AD2B7F Q35218051-3CF65B8B-F9BF-4345-98BC-A9D7FE649544 Q35231165-8451B039-D177-4B2C-99CF-31A1D7812F49 Q35419876-633B9F9E-4BBD-4A5E-B211-9D669C225171 Q35527893-98C806CA-87B5-4B07-B7FA-CE5656C8307B Q35568457-DDD3D3CE-E5EA-422C-903C-74D64FC19632 Q35577880-77593DAC-518E-4AD1-8DF2-28D9ECE0DC10 Q35755485-B42BB8C3-BA25-4E7D-92BD-51E893AC25E0 Q35797583-306E39EA-A898-419E-B6B8-7C64C4310665 Q35880791-B27C4AE5-C8CB-4E9F-8855-A190DE9BB5F1 Q35911350-0CDFCE04-420E-4237-BCB7-BB1FEB2CC2A4 Q35974341-A57414DF-4F4F-478A-BC3B-91CBFD94486F Q36010286-CFC8D821-82D6-415C-AEB4-86481401FDE2 Q36011142-124A0D3C-751E-4420-989D-8CD809C0B8D0 Q36192439-59B7E169-3CF7-42AB-BC99-93FD457AC6F5 Q36249448-6ABB9679-05F3-41BD-B572-D0F64FE69868 Q36267666-61B11FED-D678-4ECA-B208-1F4C255BF749 Q36280547-FDF5D0C6-D313-4F7D-A4B7-4DF1C6AD5262 Q36435313-51799002-43A7-4423-ACCC-C458DE442F8E Q36467468-2E85004D-D30E-4F80-AC44-327CEDD9E6B2 Q36559885-F4C87F70-D425-420C-8832-837D671E4679

P2860

Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab.

http://www.wikidata.org/entity/Q34679166

description

2010 nî lūn-bûn

@nan

2010 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Immunohistochemical methods fo ...... mphoma treated with rituximab.

@ast

Immunohistochemical methods fo ...... mphoma treated with rituximab.

@en

Immunohistochemical methods fo ...... mphoma treated with rituximab.

@nl

type

label

Immunohistochemical methods fo ...... mphoma treated with rituximab.

@ast

Immunohistochemical methods fo ...... mphoma treated with rituximab.

@en

Immunohistochemical methods fo ...... mphoma treated with rituximab.

@nl

prefLabel

Immunohistochemical methods fo ...... mphoma treated with rituximab.

@ast

Immunohistochemical methods fo ...... mphoma treated with rituximab.

@en

Immunohistochemical methods fo ...... mphoma treated with rituximab.

@nl

P1433

Q34679166-F9699D42-5F19-4511-874A-8B57CF2B27B7

P1476

Q34679166-56E2D08C-7E48-4733-BB2D-29CD6E3C83A3

P2093

Q34679166-1714F090-F55D-442A-B7FF-87B097F90F55

Q34679166-27425E22-8BFD-4E2D-98D1-903E56F83614

Q34679166-4AE6DC43-4F5E-4C65-8BDC-3589530F20DD

Q34679166-4EF6D7B3-DB3F-4D80-B8D4-50930581E738

Q34679166-521FFA4D-EFA2-4CBE-B20B-248B808A7B56

Q34679166-5E9D8097-E0B2-4032-B845-6B01008589A7

Q34679166-974A759D-F0EE-44F2-87DC-A14C25033F0E

Q34679166-C52CD2A0-2FE8-4B51-A443-D81626A459F7

Q34679166-DDF49706-7C4B-490F-9726-9BFD8043B170

P2860

Q34679166-0434D04E-FE58-488C-8EEE-1D6A50B6FF1A

Q34679166-04F1A42E-E9EC-4754-8D13-3D5688536AA4

Q34679166-08699D71-1A8F-4A5E-A34A-F613DFF980A8

Q34679166-2FE9ED5B-4DA8-4EF2-BEC8-733C143E369C

Q34679166-4B30FD3C-255C-42F0-A59B-79B07B995893

Q34679166-8DC3CC29-4C51-4906-B287-7A18DBD57BED

Q34679166-ADEEE74F-77A5-4A48-969B-1027AF0AC4E5

Q34679166-AE85C7F8-6D84-494D-B82C-EE01BAE7DB32

Q34679166-B27D25E5-7633-4D6F-869C-52707C22BF0C

Q34679166-BD9F83A9-B71F-44E6-ADE2-F3E3A17DDD03

P304

Q34679166-50887BB1-D6DF-4396-8018-03290FBCBDCA

P31

Q34679166-FFF7447F-3740-4201-852C-B94A969E3026

P356

Q34679166-E564B9BA-8512-4596-B14C-3EEC76F19CCF

P407

Q34679166-E1305662-C821-47D4-AEF8-F8D2337599A8

P433

Q34679166-28D0C99B-F6EA-41BF-B973-9B37CD0CE58E

P478

Q34679166-0A11AB0D-67EF-46D0-AD07-6CF81458B16B

P50

Q34679166-0BE3FF19-14C7-41F3-B00B-479CE8B472E9

Q34679166-376EA487-6AAA-4378-9889-89FCA2063FD2

Q34679166-8148B362-A72A-4FE5-B44F-E537DEEDCDEE

Q34679166-88B6D85B-A432-47BB-88F1-3395C135F353

Q34679166-95A6FC5C-9E2D-4517-9CD3-924917CB7500

Q34679166-F448ED6C-D10B-4339-B31E-7C525EA8BE58

P577

Q34679166-EEF022E1-4D19-48C8-8887-143BD231F6A9

P698

Q34679166-1EC133B1-A094-456E-BA30-4F9739BAF4C6

P921

Q34679166-3F153AD5-64D5-4E59-AA3F-716944509056

Q34679166-BB77BE6F-A6FE-43F9-A968-2BDBFAB16E41

P932

Q34679166-913ED4F4-ED4B-4915-B948-3F2DD524F3FC

P356

JCO.2010.30.0368

P1433

Journal of Clinical Oncology

P1476

Immunohistochemical methods fo ...... mphoma treated with rituximab.

@en

P2093

Andreas Rosenwald

http://www.w3.org/2001/XMLSchema#string

Georg Lenz

http://www.w3.org/2001/XMLSchema#string

German Ott

http://www.w3.org/2001/XMLSchema#string

Kai Fu

http://www.w3.org/2001/XMLSchema#string

Louis M Staudt

http://www.w3.org/2001/XMLSchema#string

Lynette M Smith

http://www.w3.org/2001/XMLSchema#string

Paul N Meyer

http://www.w3.org/2001/XMLSchema#string

Rita M Braziel

http://www.w3.org/2001/XMLSchema#string

Timothy C Greiner

http://www.w3.org/2001/XMLSchema#string

P2860

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

Phase II study of dose-adjusted EPOCH and rituximab in untreated diffuse large B-cell lymphoma with analysis of germinal center and post-germinal center biomarkers

A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma

Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling

Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray

A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy

Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma

Stromal gene signatures in large-B-cell lymphomas

Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications--a study from the Lunenburg Lymphoma Biomarker Consortium.

Rituximab therapy in malignant lymphoma.

P304

200-207

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2010.30.0368

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

29

http://www.w3.org/2001/XMLSchema#string

P50

Randy D Gascoyne

Dennis D Weisenburger

P577

2010-12-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21135273

http://www.w3.org/2001/XMLSchema#string

P921

immunohistochemistry

P932

3058275

http://www.w3.org/2001/XMLSchema#string